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2. Introduction 
Cardiovascular diseases, and in particular, cardiac arrhythmias, such as ventricular 
fibrillation have a leading role in mortality in the developed countries. The most serious 
ventricular arrhythmia—ventricular fibrillation—causes the death of more than 3 000 000 
people all over the world and 300-350 000 people in the USA and Europe annually, which 
statistically means that one person dies in every minute on each continent. In Hungary exact 
data are not available, but according to calculations there are 25-26 000 sudden cardiac death 
cases annually, meaning 50-60 deaths per day. In the majority of the cases sudden cardiac 
death occurs when victims are not in hospital, consequently, survival probability is very low. 
Most frequently (50%) the background of the on-the-spot diagnosed circulation collapse is 
ventricular tachycardia /fibrillation/. Sudden cardiac death is often the very first sign of the 
symptom-free cardiovascular disease. Sudden cardiac death is a complex national health 
problem affecting families and having social and economic outcomes, since it is the head of 
the family, a seemingly healthy man, who dies tragically in most of the cases. Survivors of the 
crisis can live a life of full volume in good conditions provided that they get the most 
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appropriate treatment. Accordingly, cardiac arrhythmias represent a major area of 
cardiovascular research. One of the main goals of pharmacological research is to develop a 
safe ventricular antiarrhythmic drug that can be applied either in acute cases or for treating 
postinfarction patients. 
Concepts regarding the treatment of cardiac arrhythmias changed significantly in the past 
decade, owing to the revolutionary developing electrophysiological methodes (patch-clamp, 
molecular biology). The Cardiac Arrhythmia Supression Trial (CAST) [1] showed that 
flecainide and encainide, two Class I/C sodium channel blocker antiarrhythmic drugs, 
increased mortality rates approximately threefold compared with placebo due to 
proarrhythmic effects. Consequently, since the CAST, the interest of drug development and 
treatment of ventricular tachycardia (VT) and atrial fibrillation (AF) has been shifted toward 
those agents that prevent and terminate reentrant arrhythmias by prolonging the action 
potential duration (APD) and effective refractory periode (ERP), resulting in an increase in 
arrhythmia wavelength and a block development within the reentrant circuit. 
Class m antiarrhythmic action, i.e.lengthening of cardiac action potential duration (APD) 
[2] and prolongation of the repolarization, is usually caused by blockade of one or more 
potassium channels. Sodium channels are not affected, thus conduction velocity remains 
unchanged. A great number of non-cardiac drugs do result in lengthening of repolarization in 
both ventricular muscle cells and Purkinje fibers by using a similar mode of action [3]. 
The repolarization of the cellular membrane is achieved mainly by the rapid delayed 
rectifier potassium current (IRI). In most species, including humans, it is made of a rapid (IRT) 
and a slow (IRS) component [4]. These two components are different in terms of drug 
sensitivity as well as in the characteristics and kinetics of their voltage-current relationships. 
Selective blockers of IRT (d-sotalol, ibutilide, dofetilide) significantly lengthen the APD in 
heart muscle cells, and their antiarrhythmic effect has been proven in human as well. 
However, the Suppression With Oral D-sotalol (SWORD) trial [5] has showed that d-sotalol 
increased the mortality (presumably due to Torsade de Pointes arrhythmia) in postinfarction 
patients with ventricular arrhythmia. 
This adverse effect of d-sotalol on mortality is most likely due to its bradycardia-dependent 
proarrhythmic („torsadogenic") action and most other pure Class III compounds might act in a 
similar harmful way. The outcome of the SWORD study has seriously affected the 
6 
development of selective Class III compounds, namely, research on several compounds 
belonging to this group has been discontinued [6]. 
Most drugs with pure Class III action prolong APD more at slow rates and produce little or 
no change at fast ones. This phenomenon, termed reverse rate-dependency [7] is particularly 
evident in M cells and Purkinje fibers [8]. The reverse rate-dependent nature of APD 
lengthening effect of most pure Class HI drugs seriously limits the antiarrhythmic efficacy by 
compromising their ability to prolong APD and refractoriness when most needed, namely 
during tachycardia. In addition, it contributes importantly to the proarrhythmia caused by 
Class EI agents because of the excessive prolongation of repolarization. Emphasis was 
therefore shifted toward developing compounds with a multifaceted ("hybrid") 
pharmacological profile [9,10] with multiple molecular targets suggested by the "Sicilian 
gambit" [11]. Many investigators are now considering that application of drugs with multiple 
actions like amiodarone would represent a possible effective way to treat both ventricular and 
supraventricular arrhythmias [12]. Within the group of these drugs having multiple molecular 
targets, RP 58866, and its enantiomer, terikalant were first considered as selective blockers of 
the inward rectifier potassium current (Iki) [13]. These compounds exhibited efficacy in 
experimental arrhythmias [14], suggesting that block of IKI may be a useful antiarrhythmic 
mechanism with lower incidence of the torsade de pointes ventricular tachycardias [15]. The 
in vitro electrophysiological effects of terikalant, this new investigational antiarrhythmic drug 
with largely unknown cellular mode of action is being extensively studied. I investigated the 
cellular mechanisms of action of terikalant in canine isolated ventricular muscle and Purkinje 
fibers, by applying the standard microelectrode technique. 
Ventricular repolarization is governed by a fine balance between inward currents, such as 
the fast sodium (INs) and the L-type calcium (Ica) currents, and outward currents, such as the 
transient outward (It0), rapid delayed rectifier (IKI), slow delayed rectifier (IKS) and inward 
rectifier (IKI) potassium currents. Under normal conditions impairment or block of one type of 
outward potassium currents can not be expected to cause excessive and potentially dangerous 
APD lengthening, since the other potassium currents may provide sufficient repolarizing 
capacity, which can be considered as a 'repolarization reserve'. However, in situations where 
the density of one or more types of potassium channels is decreased by inheritance or 
remodelling [16,17] inhibition of other potassium channels may lead to unexpectedly 
augmented APD prolongation, resulting in proarrhythmic reactions. Genetic channelophathies 
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of certain potassium channels, which normally contribute to repolarization, can attenuate the 
capability of the heart to repolarize. 
Recently, experiments carried out in our lab suggested that selective IRS block only 
minimally lengthens repolarization in normal dog ventricular muscle. However, when the 
'repolarization reserve' is attenuated by E-4031 or veratrine [18], IKS block substantially 
delays repolarization. One of the goals of my PhD project was to shed more light on the 
possible role of the 'repolarization reserve' and the interaction of different potassium channels 
in cardiac repolarization using the dog ventricular muscle as a model system. 
The rapid component of the delayed rectifier potassium current (IRT) has been identified in 
several mammalian species [19,20,21], including human [22,23,24,25]. Pharmacological 
agents that selectively block IRT (e.g., E-4031, sotalol, and dofetilide) markedly increase APD, 
QT duration, and ventricular refractoriness, and high doses of these drugs are associated with 
the induction of Torsade de Pointes [26,27]. Mutations in ion channel genes, including 
HERG and KCNE2, that suppress IRT result in a specific form of the inherited long QT 
syndrome, LQT2, are also associated with rhythm disorders and an increased incidence of 
Sudden Cardiac Death (SCD) [28]. As such, IRT plays a major role in action potential 
repolarization in health and in specific cases of arrhythmogenesis [29]. 
The role of the slow delayed rectifier potassium current (IRS) in human ventricular muscle 
action potential repolarization, on the other hand, has been often debated. As with IRT, IRS has 
been identified in several mammalian species [19,20,21], including humans [24,29] and 
mutations in KCNQ1 and KCNE1, the alpha and beta-subunits of the IRS potassium channel, 
are associated with another specific form of the inherited long QT syndrome, LQT1 [28]. In 
contrast, we previously reported that complete pharmacological block of IRS, by either 
chromanol 293B or L-735,821, has little effect on APD in isolated dog and rabbit ventricular 
muscle [30,31] over a wide range of physiologic pacing frequencies. These findings led us to 
speculate that IRS normally plays little role in ventricular muscle action potential 
repolarization. However, when APD is abnormally long, IRS likely provides an important 
safety mechanism that when removed increases arrhythmic risk. Our previously reported 
findings have now been confirmed by those of other investigators [31] and supported by 
computer simulations that suggest that IRS does not play a role in adaptations of APD to 
changes in heart rate [32]. However, the role of IRS in human ventricular muscle remains 
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controversial; although, our preliminary characterization of Irt [25] and [29] in isolated 
human ventricular myocytes suggests that these currents behave much the same as they do in 
isolated dog [19] and rabbit [30,20] ventricular myocytes. The purpose of the present study, 
therefore, was to confirm our initial findings while better elucidating the role of IRS in normal 
human ventricular muscle action potential repolarization. 
Prolongation of cardiac repolarization is an important mode of action of pure Class III 
drugs (i.e. those that block Irt selectively). These compounds should be applied with caution, 
since they result in increased mortality due to several reasons. First, they increase the 
inhomogenity of repolarization and consequently that of the refractoriness. Second, the 
reverse use-dependent effect of these drugs (i.e. that they cause greater prolongation of the 
APD at slow versus rapid rates of stimulations) is also disadvantageous because at slow heart 
rate it may cause early afterdepolarizations (EAD) and consequently Torsade de Pointes 
(TdP) type ventricular arrhythmias. 
In our study we investigated the rate dependent effect of the different drugs. 
Another arrhythmogen factor that can result in ventricular arrhythmias occuring in 
myocardiac ischaemia or poisoning with digitalis is delayed afterdepolarization (DAD), which 
arises in heart muscle cells following Ca2+ overload. Reducing the incidence of these two 
trigger mechanismus (EAD and DAD) or their pharmacological blockade would be extremely 
desirable from a clinical point of view. 
Maintenance of the Ca2+ homeostasis in the myocardium is mainly regulated by the 
sodium-calcium exchanger (NCX) [33]. It is known that NCX, at the forward mode, extrudes 
Ca2+ from the cell to the extracellular space during diastole, at relatively low free cytoplasmic 
Ca2+ concentration and negative transmembrane potential. Since the extrusion of one Ca2+ is 
coupled with 3 Na+ entering the cell, during the forward mode of the NCX net inward current 
is carried, which can cause substantial depolarization leading to early (EAD) and delayed 
(DAD) after-depolarizations, especially when intracellular Ca2+ is elevated. EAD and DAD is 
generally thought to play an important role in arrhythmogenesis [34,35], especially in 
conditions where potassium conductance is decreased, such as in heart failure [36]. Therefore 
one may speculate that specific blockers of NCX can be potential antiarrhythmics in 
dysrhythmias related to Ca2+ overload. This hypothesis could not be directly tested since the 
available NCX inhibitors, at least in higher concentrations, also decreased the L-type calcium 
current (ICa) which in turn decreases intracellular Ca2+ load, thereby indirectly changing the 
9 
magnitude of NCX. Recently it was found that KB-R7943, an effective inhibitor of NCX in 
the reverse mode but not in the forward mode [37], reduced the incidence of ischaemia and 
reperfiision arrhythmia induced by calcium overload [38,39]. However, KB-R7943 also 
inhibits the L-type calcium current [40] which makes the interpretation of its antiarrhythmic 
effect rather uncertain. Therefore, we investigated the effect of ORM-10103, a newly 
developed NCX inhibitor devoid of Ica blocking property, on the NCX and Ica currents of dog 
ventricular myocytes, and also on the formation of EAD and DAD in the dog ventricular 
muscle and Purkinje fibers, using the conventional microelectrode technique. 
3. Major specific experimental aims 
a) To investigate the in vitro electrophysiological effects of terikalant, this new 
investigational antiarrhythmic drug with largely unknown cellular mode of action. 
b) To study the possible role and the interaction of different potassium channels in 
cardiac repolarization in dog ventricular muscle. 
c) To elucidate the role of IRT and IRS in normal human ventricular muscle. 
d) To study the effect of ORM-10103, a newly developed NCX inhibitor devoid of Ica 
blocking property, on the NCX and Ica currents of dog ventricular myocytes, and 
also on the formation of EAD and DAD in the dog ventricular muscle and Purkinje 
fibers. 
4. Methods 
4.1 Experimental animals 
Mongrel dogs of either sex (body weights 8-20 kg) were used for the study. All 
experiments were carried out in compliance with the Guide for the Care and Use of 
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Laboratory Animals (U.S.A: NIH publication No 85-23, revised 1985). The protocols were 
approved by the Review Board of the Comittee on Animal Research of the University of 
Szeged (54/ 1999). 
4.2 Preparations 
Endocardial preparations (obtained from papillary muscles) were isolated from the right 
ventricle of hearts removed from anaesthetized (sodium pentobarbital 30 mg/kg iv.) mongrol 
dogs of either sex. Free running false tendons of Purkinje fibers were excised from the right or 
the left ventricle of the hearts. The preparations were placed in a tissue bath and allowed to 
equilibrate for at least 2 hours while superfused with oxygenated (95 % 02-5 % CO2) 
Tyrode's solution (flow 4-5 ml/min) wanned to 37 °C (pH 7.3 ± 0.5) and containing (in 
mM/1) NaCl 123, KC14.7, NaHC03 20, CaCl21.8, MgCl2 0.8 and D-glucose 10. Preparations 
were oxygenated also in the tissue bath directly. 
4.3 Conventional microelectrode technique 
Adult mongrel dogs (8 ± 14 kg) of either sex were used. Following anaesthesia (sodium 
pentobarbitone, 30 mg kg-1 administered intravenously), the heart of each animal was rapidly 
removed through right lateral thoracotomy. The hearts were immediately rinsed in oxygenated 
Tyrode's solution containing (in mM): NaCl, 115; KC1,4; CaCl2,1.8; MgCl2,1; NaHC03,20; 
and glucose, 11. The pH of this solution was 7.40 ± 7.45 when gassed with 95% O2 and 5% 
CO2 at 37 °C. Tip of the papillary muscles obtained from the right ventricle were individually 
mounted in a tissue chamber (volume 50 ml). Each ventricular preparation was initially 
stimulated (HSE (Hugo Sachs Elektronik) stimulator type 215/n, March-Hugstetten, 
Germany) at a basic cycle length (BCL) of 1000 ms (frequency=l Hz), using 2 ms rectangular 
constant voltage pulses isolated from ground and delivered across bipolar platinum electrodes 
in contact with the preparation. Each preparation was allowed at least 1 h to equilibrate while 
they were continuously superfused with Tyrode's solution. Temperature of the superfusate 
was kept constant at 37 °C. Transmembrane potentials were recorded using conventional 
microelectrode techniques. Microelectrodes filled with 3M KC1 and having tip resistances of 
15-20 MOhm were connected to the input of a high impedance electrometer (HSE 
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microelectrode amplifier type 309), which was connected to ground. The first derivative of 
transmembrane potentials was electronically obtained by an HSE differentiator (type 309). 
The voltage outputs from all amplifiers were displayed on a dual beam memory oscilloscope 
(Tektronix 2230 100 MHz digital storage oscilloscope, Beaverton, OR, U.S.A.). 
The maximum diastolic potential, action potential amplitude and action potential duration 
(APD) measured at 50 and 90% repolarization (APD50-90) were obtained using a software 
developed in our department (HSE-APES) on an IBM 386 microprocessor based personal 
computer connected to the digital output of the oscilloscope. After control measurements the 
preparations were superfused for 60 min with Tyrode's solution containing the compound 
under study, and then the electrophysiological measurements were resumed. 
4.4 Patch-clamp measurements 
Ventricular myocytes were enzymatically dissociated from hearts which were removed 
from mongrel dogs of either sex weighing 10-20 kg following anaesthesia (sodium 
pentobarbital, 30 mg kg"1 i.v.). The hearts were immediately placed in cold (4°C) normal 
Tyrode solution. A portion of the left ventricular wall containing an arterial branch large 
enough to cannulate was then perfused in a modified Langendorff apparatus at a pressure of 
60 cmH20 with solutions in the following sequence: (1) normal Tyrode solution (10 min), (2) 
Ca2+-free solution (10 min), and (3) Ca2+-free solution containing collagenase (type I, 0.66 mg 
ml"1, Sigma) and bovine serum albumin (fraction V, fatty acid free, 2 mg ml"1, Sigma) (15 
min). Protease (type XIV, 0-12 mg ml"1, Sigma) was added to the final perfusate and another 
15-30 min of digestion was allowed. Portions of the left ventricular wall judged to be well 
digested were diced into small pieces and placed either in Kraft-Briihe (KB) solution or in 
Ca2+-free solution supplemented with CaCU (1.25 mM) for 15 min. Next, these tissue samples 
were gently agitated in a small beaker to dislodge single myocytes from the extracellular 
matrix. All cell suspensions resulting from this dissociation procedure contained a mixture of 
subepicardial, midmyocardial and subendocardial myocytes. During the entire isolation 
procedure, solutions were gassed with 100% O2 while their temperatures were maintained at 
37 °C. Myocytes were allowed to settle to the bottom of the beaker for 10 miri, and then the 
supernatant was replaced with fresh solution. This procedure was repeated three times. 
Myocytes placed in KB solution were stored at 4°C; those placed in Tyrode solution were 
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maintained at 12-14°C prior to experimentation. Cells that were stored in KB solution or 
immediately placed in 1-25 mM calcium containing solution had the same appearance and 
there were no discernible differences in their characteristics. 
Compositions of solutions used for cell isolation. Normal Tyrode solution (mM): NaCl 
135, KC1 4.7, KH2P04 1-2, MgS04 1.2, Hepes 10, NaHC03 4.4, glucose 10 and CaCl2 1.0 
(pH 7.2 adjusted with NaOH). Ca2+-free solution (mM): NaCl 135, KC1 4.7, KH2P04 1-2, 
MgS04 1.2, Hepes 10, NaHC03 4.4, glucose 10 and taurine 20 (pH 7.2 adjusted with NaOH). 
KB solution (mM): KOH 90, L-glutamic acid 70, taurine 15, KC1 30, KH2P04 10, MgCl2 0.5, 
Hepes 10, glucose 11 and EGTA 0.5 (pH 7-3 adjusted with KOH). 
4.5 Whole cell configuration of the patch-clamp technique 
One drop of cell suspension was placed within a transparent recording chamber mounted 
on the stage of an inverted microscope (TMS, Nikon, Tokyo, Japan), and individual myocytes 
were allowed to settle and adhere to the chamber bottom for at least 5 min before superfusion 
was initiated. Only rod shaped cells with clear cross striations were used. HEPES buffered 
Tyrode's solution served as the normal superfusate. This solution contained (mM): NaCl 144, 
NaH2P04 0.33, KC14.0, CaCl2 1.8, MgCl2 0.53, Glucose 5.5, and HEPES 5.0 at pH of 7.4. 
Patch-clamp micropipettes were fabricated from borosilicate glass capillaries (Clark, 
Reading, U.K.) using a P-97 Flaming/Brown micropipette puller (Sutter Co, Novato, CA, 
U.S.A.). These electrodes had resistances between 1.5 and 2.5 MI2 when filled with pipette 
solution containing (in mM): K-aspartate 100, KC1 45, ATP 3, MgCl2 1, EGTA 10 and 
HEPES 5. The pH of this solution was adjusted to 7.2 by KOH. Cell capacitance 
(114.4±26.2) was measured by applying a 10 mV hyperpolarizing pulse from -10 mV. The 
holding potential was -90 mV. The capacity was measured by integration of the capacitive 
transient divided by the amplitude of the voltage step (10 mV). Measuring K+ currents, 
nisoldipine (1 mM) (gift from Bayer AG, Leverkusen, Germany) was added to the external 
solution to eliminate inward L-type Ca2+ current (Ica). The rapid IRT and slow IRS components 
of the delayed rectifier potassium current were separated by using the selective IR, blocker E-
4031 (1 mM, Institute for Drug Research, Budapest, Hungary) or the IRS blocker L-735,821 
(100 nM, a gift from Merck-Sharpe & Dohme, West-Point, PA, U.S.A.). Membrane currents 
were recorded with Axopatch-ID and 200B patch-clamp amplifiers (Axon Instruments, Union 
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City, CA, U.S.A.) using the whole-cell configuration of the patch-clamp technique. After 
establishing a high (1-10 GOhm) resistance seal by gentle suction, the cell membrane beneath 
the tip of the electrode was disrupted by suction or by application of 1.5 V electrical pulses 
for 1 ± 5 ms. The series resistance was typically 4-8 MO before compensation (50-80%, 
depending on the voltage protocols). Experiments where the series resistance was high, or 
substantially increased during measurement, were discarded. Membrane currents were 
digitized using a 333 kHz analogue-to-digital converter (Digidata 1200, Axon Instruments) 
under software control (pClamp 6.0 and 7.0 Axon Instruments). Analyses were performed 
using Axon (pClamp 6.0) software after low-pass filtering at 1 kHz. All patch-clamp data 
were collected at 37 °C. 
4.6 Human experiments 
Hearts were obtained from organ donors whose hearts were explanted to obtain pulmonary 
and aortic valves for transplant surgery. Before cardiac explanation, organ donor patients did 
not receive medication, except dobutamine, furosemide, and plasma expanders. The 
investigations conform to the principles outlined in the Declaration of Helsinki [41] and all 
experimental protocols were approved by the Albert Szent-Györgyi Medical University 
Ethical Review Board (No. 51-57/1997). Proper consent was obtained for use of each 
individual's tissue for experimentation. 
Human tissue preparation 
Action potentials were recorded in ventricular trabeculae and papillary muscle preparations 
(< 2 mm in diameter, n =42) obtained from the right ventricles of 24 undiseased human donor 
hearts (17 male and 7 female, age = 45.7 ± 3.8 years) using conventional microelectrode 
techniques. After explantation, each heart was perfused with cardioplegic solution and kept 
cold ( 4 - 6 °C) for 2-4 horns prior to dissection. Trabeculae and papillary muscles were then 
excised and mounted in a tissue chamber (volume « 50 ml) perfused with oxygenated (95% 
0 2 + 5% C02) modified Tyrode's solution containing (in mM): NaCl, 115; KC1, 4; CaCl2,1.8; 
MgCl, 1; NaHCOj, 20; and glucose, 11. The pH of this solution was 7.35 to 7.45 at 37 °C. 
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Action potential measurements in multicellular preparations: 
Initially, each preparation was stimulated at a basic cycle length of 1000 ms (frequency = 1 
Hz), using 2 ms long rectangular constant voltage pulses isolated from ground and delivered 
via bipolar platinum electrodes in contact with the preparation using an EMG 4767 type 
stimulator (Medicor Ltd, Budapest, H-1147, Hungary). One hour or more was allowed for 
each preparation to equilibrate while continuously superfused with Tyrode's solution warmed 
to 37 °C. Transmembrane potentials were recorded using a conventional glass microelectrode 
filled with 3 M KC1 with a tip resistance of 5-20 MQ connected to a high impedance 
electrometer (Bio-Logic VF102, CLAIX, F-38640, France) referenced to ground. The first 
derivative of transmembrane potential (dV/dt) was electronically derived using a Bio-Logic 
DV-140 (Claix, F-38640, France) differentiator designed and calibrated to have a linear 
response over the range of 10 to 1000 V/s. Amplifier outputs were digitized using an ADA 
3300 analog-to-digital converter (Real Time Devices Inc, State College, PA 16804, USA) 
with a maximum sampling rate of 50 kHz connected to an IBM compatible personal 
computer. Data was stored and analyzed on the PC and also monitored on a dual beam 
memory oscilloscope (Tektronix 2230, Beaverton, OR 97077, USA). Resting membrane 
potential (RP), action potential amplitude (APA), and action potential durations (APD), 
measured at 50% and 90% repolarization (APD50 and APD90), were automatically measured 
with software developed in our laboratory (APES, Hugo Sachs Elektronik, March-Hugstetten, 
D-79229, Germany). Stimulation pulses were also controlled by PC software providing 
constant current pulses with programmed timing and amplitudes to the preparation via a EMG 
47671 type signal isolator (Medicor Ltd, Budapest, H-l 147, Hungary). 
In each experiment, baseline action potential characteristics were first obtained during 
superfusion with normal 37 °C Tyrode's solution while continuously pacing at a basic cycle 
length of 1000 ms, followed by a run of changing pacing cycle lengths (300, 400, 500, 700, 
1000, 1500, 2000, 3000 and 5000 ms) sequentially applied for 25 beats each. This procedure 
allowed action potential parameters to be quickly obtained at each pacing cycle length after a 
"quasi steady-state" was established. Recordings were continuously monitored to confirm 
one-to-one activation throughout the procedure. 
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After baseline measurements were obtained, each preparation was superfused with 
Tyrode's solution containing a single test drug diluted to the proper concentration for 40 to 60 
minutes before measurements were repeated at 3 min intervals in the continued presence of 
the test drug until less than a 5% change occurred in action potential characteristics between 
subsequent samples. When microelectrode impalement was lost, reimpalement was 
attempted. If action potential characteristics recorded with the new impalement deviated by 
more than 5% from the preceding ones, the experiment was terminated, and results were 
excluded from evaluation. 
4.7 Drugs 
Terikalant (RP62719, Rhone-Poulenc Rorer, France) was dissolved in dimethyl-sulphoxide 
(DMSO) at concentrations of 1 and 100 mM. 
Chromanol 293B (gift from Aventis Pharma, Frankfurt, Germany) and dofetilide (Aventis 
Pharma, Frankfurt, D-65926, Germany) were dissolved in 100% DMSO to make 1 mM and 
10 mM stock solutions. The stock solutions were further diluted in the tissue bath to obtain 
the desired final drug concentrations. 
Iicr blockers D-sotalol (Bristol-Myers Squibb Co., Wallingford, CT 06492, USA) and E-
4031 (Institute for Drug Research Ltd., Budapest, H-1045, Hungary) were prepared daily 
from aqueous stock solutions (30 mM and 10 mM, respectively) to obtain the final drug 
concentration examined. IRS blockers chromanol 293B (Institute for Drug Research, Budapest, 
Hungary), HMR-1556 (Aventis Pharma) and L-735,821 (Merck-Sharpe & Dohme Co, West 
Point, PA 19486, USA) were similarly diluted from stock solutions (10 mM and 1 mM , 
respectively) containing 100 % DMSO. This procedure resulted in a 0.01% DMSO 
concentration when the effects of the drugs were examined. This and the lower DMSO 
concentrations alone did not affect action potential characteristics in separate studies. 
4.8 Statistical analysis 
Results were compared using Student's t-tests for paired and impaired data. Differences 
were considered significant when P< 0.05. Data are expressed as mean±standard error of the 
mean (S.E.M.) 
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5. Results 
5.1 Goal I: To investigate the in vitro electrophysiological effects of terikalant, this new 
investigational antiarrhythmic drug with largely unknown cellular mode of action. 
5.1.1 Effects of terikalant on the action potential parameters in canine ventricular muscle 
and Purkinje fibers 
The effect of terikalant on the duration of the action potential and on the maximum 
velocity of the action potential upstroke (Vmax) at a cycle length of 1000 ms was investigated 
in concentrations of 1, 2.5, 10 and 20 pM in right ventricular papillary muscle preparations. 
Fig. 1A shows that terikalant concentration-dependently lengthened the action potential, 
which effect was more pronounced when the duration of the action potential was measured at 
50 % of repolarization. In Fig. IB the effect of terikalant on Vmax at the same concentrations is 
shown. At low concentrations (1 and 2.5 pM) terikalant did not affect the Vmax, although a 
small but non-significant increase was observed at 2.5 pM concentration, which was likely 
due to an improved microelectrode-cell connection observed in some experiments with time. 
However, application of terikalant at 10 and 20 pM concentration resulted in a marked and 
concentration-dependent decrease in Vmax. 
A detailed analysis of the action potentials recorded before and after the application of 
terikalant was carried out at 2.5 and 10 pM concentrations. Representative traces of the action 
potentials and the first derivatives of the action potential upstroke, dV/dt, recorded before and 
after administration of terikalant in canine ventricular muscle and Purkinje fibers are shown in 
Fig. 2. Terikalant, investigated at 2.5 pM concentration, significantly lengthened the action 
potential durations measured both at 50 and 90 % of repolarization from 190.4 ± 7.3 to 216.4 
± 8.2 ms (n = 6, P < 0.05) and from 224.7 ± 6.9 to 259.8 ± 9.6 ms (n = 6, P < 0.05), 
respectively, in papillary muscle without causing considerable change in the maximum 
diastolic potential, action potential amplitude and Vmax. However, at 10 pM concentration, in 
addition to the lengthening of the action potential duration from 209.2 9.4 to 224.9 10.3 and 
from 253.9 ± 7.7 to 288.9 ± 7.4 ms (n = 6, P < 0.05), measured at 50 and 90 % of 
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repolarization, respectively, the drug also caused a significant decrease in Vmax from 211.8 ± 
14.1 to 183.3 ± 14.5 V/s (n = 6, P < 0.05). In Purkinje fiber 2.5 pM terikalant significantly 
lengthened the action potential duration measured at 90 % of repolarization from 241.9 ± 13.2 
to 320.8 ± 16.2 ms (n = 6, P < 0.05) without affecting the action potential duration measured 
at 50 % of repolarization and the maximum diastolic potential. Also, Vmax was significantly 
decreased by the drug from 747.4 ± 68.6 to 586.3 ± 79.2 V/s (n = 6, P < 0.05) and a slight but 
significant reduction in action potential amplitude from 132.6 ± 2.4 to 127.6 ± 3.4 mV was 
also found in Purkinje fibers in the presence of 2.5 pM terikalant (Table 1, Fig. 2C). 
5.1.2 Frequency-dependent effects of terikalant in ventricular papillary muscle and 
Purkinje fiber 
Fig. 3A and 3B show that the drug, at a concentration of 2.5 pM, lengthened the duration 
of the action potential measured at 90 % of repolarization in a reverse frequency-dependent 
manner both in papillary muscle and Purkinje fibers, with a more pronounced reverse 
frequency dependence observed in Purkinje fibers. 
In papillary muscle, frequency-dependent effect of terikalant (2.5 and 10 pM) on the 
maximum upstroke velocity of the. action potential (Vmax) was also investigated. Vmax was 
unaffected by the drug given in the lower (2.5 pM) concentration at any given stimulation rate 
(Fig. 4A). However, as shown in Fig. 4B 10 pM terikalant caused a rate-dependent depression 
in the maximal upstroke velocity of the action potential in this preparations, ie. decreasing 
Vmax more at high than at slow stimulation rate. 
5.1.3 Offset and onset kinetics of Vmax block 
Fig. 5B shows the offset kinetics of Vmax block induced by 10 pM terikalant in papillary 
muscle preparations. The Vmax values of premature beats elicited once after every 10th basic 
beat (at a cycle length of 1000 ms) are plotted as a function of diastolic interval (interval 
between the 90% repolarization of the basic beat and the upstroke of the premature beat). The 
recovery curves illustrated in Fig. 4B show that the drug, in addition to the fast recovery (< 50 
ms) which presumably reflects the drug free sodium channels, induced a slow phase of 
recovery of Vmax with a time constant (r) of 2956 ± 696 ms (n = 6). 
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The onset kinetics of Vmax block induced by 10 pM terikalant was also studied in dog right 
ventricular papillary muscle (Fig. 5A). Preparations were continuously stimulated at a cycle 
length of 1000 ms. The stimulation was interrupted for 1 min, and then a train of 40 stimuli 
was applied with a cycle length of 500 ms (Fig. 5A). In control conditions, there was only a 
minor change between the first and last Vmax values in the train. In the presence of 10 pM 
terikalant, however, a marked use-dependent Vmax block developed with an onset kinetic rate 
constant of 0.6 ± 0.1 beat-1 (n = 6). 
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Fig. 1: Concentration-response characteristics of the effect of terikalant on duration of the 
action potential measured at 50 and 90 % of repolarization (A) and the maximum upstroke 
velocity of the action potential (Vmax) (B) at a cycle length of 1000 ms in dog papillary 
muscles. Terikalant was applied at concentrations of 1, 2.5, 10 and 20 pM (n = 4-
6/concentration). 
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Fig. 2: Representative traces of the transmembrane action potential (top) and the first 
derivative of the action potential upstroke, Vmax (bottom) recorded from right ventricular 
papillary muscle (A and B) and from Purkinje fiber in control conditions and in the presence 
of 2.5 pM (A and C) and 10 pM (B) terikalant. Traces were recorded at a cycle length of 1000 
ms. 
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Fig. 3: Cycle length dependent effect of terikalant (2.5 pM) on the action potential duration 
measured at 90 % of repolarization in right ventricular papillary muscle (A) and Purkinje fiber 
(B) (n = 6). 
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Fig. 4: Cycle length dependent effect of terikalant on the maximum upstroke velocity of 
the action potential (Vmax) in right ventricular papillary muscle at the concentration of 2.5 pM 
(A) and 10 pM (B) (n = 6). 
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Fig. 5: Effect of 10 pM terikalant on the onset kinetics of Vmax block (A) and on 
recovery of VmaX from inactivation (B) in canine right ventricular papillary muscle (n = 6). 
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5.2 Goal II: To study the possible role and the interaction of different potassium channels 
in cardiac repolarization in dog ventricular muscle. 
5.2.1 Effect of Iks and combined Iks and I& inhibition on the APD 
Chromanol 293B is considered as an effective and relatively selective blocker of IRS 
(Busch et al., 1996). In our experiments we used 10 pM chromanol 293B since at higher 
concentrations the compound was reported also to block It0 (Bosch et al., 1998; Sun et al., 
2001) or possibly other current(s). In order to establish the selectivity of chromanol 293B on 
IRS we have investigated the possible effects of chromanol 293B on various transmembrane 
potassium currents. In all experiments L-type calcium current (Ica) was fully blocked by 
addition of 1 pM nisoldipine. 
IRI was measured by applying 36 s long ramp pulses from -120 mV to +60 mV from the 
holding potential of -90 mV at the pulse frequency of 0.02 Hz. As Figure 6A shows the 
current traces, which represent IRI, were overlapping and therefore indistinguishable from 
each other indicating that 10 pM chromanol 293B did not affect IRI. The transient outward 
current (It0) was elicited by 300 ms long test voltage pulses to between -20 and 50 mV from 
the holding potential of -90 mV with 0.33 Hz pulse frequency. The amplitude of the current 
was determined as the difference of the peak current at the start of the pulse and the steady-
state current level measured at the end of the pulse. Figure 6B show that 10 pM chromanol 
293B did not affect significantly It0. The rapid delayed rectifier current (IRT) was measured by 
1 s long test voltage pulses to between -10 and 50 mV with pulse frequency of 0.05 Hz. The 
holding potential in these experiments was -40 mV. The deactivating so-called tail current 
was measured as IRT after returning the voltage from the test potential to -40 mV. The 
amplitude of the Irt tail current was determined as the difference between the peak tail current 
and the holding current level at -40 mV. Figure 6C show that chromanol 293B, even at the 
high 100 pM concentration, exerted only minimal effect on IRT. In these experiments IRS was 
blocked by 100 nM L-735,821. 
The slow delayed rectifier (IRS) was measured by 5 s long test voltage pulses to between 
-20 and +50 mV with the pulse frequency of 0.1 Hz. The holding potential in these 
experiments was -40 mV. IR, was completely blocked by 2 pM E-4031. The deactivating IRS 
tail current was measured after returning the voltage from the test potential to -40 mV. The 
amplitude of the IRS tail current was determined as the difference between the peak tail current 
24 
and the holding current level at -40mV. Figure 6D shows that 10 pM chromanol 293B caused 
a more than 50% inhibition of IKS-
These experiments suggested that chromanol 293B at 10 pM can be applied as a tool 
inhibiting IRS rather specifically. 
Figure 7 shows that 10 pM chromanol 293B alone lengthened APD only to a small extent 
(<7%) in dog right ventricular papillary muscle at stimulation cycle lengths ranging from 300 
to 5000 ms. However, when the same concentration of chromanol 293B was added to 
preparations in which IRT was previously blocked by the specific IR, blocker dofetilide 
(1 pM), it induced a marked and significant further prolongation of the APD (Figure 8), 
suggesting a strong additive effect of the two compounds. 
5.2.2 Effect of Iki and combined Iki and inhibition on the APD 
It was reported that a low concentration of BaCl2 inhibited IRI in cardiac myocytes [42]. IRI 
and IT0 were measured as previously described. Since BaCl2 markedly reduced IRI, which 
appeared as a voltage independent background current when measuring IRT and IRS, the 
following protocols were applied to determine the effect of BaCh on IR, and IRJ. First the 
previously described voltage protocols were used in control condition. Then 10 pM BaCI2 
was added, and the voltage protocols were repeated. To distinguish between the effect of 
BaCl2 on IRI and W I R S , 2 pM E - 4 0 3 1 or 1 0 0 nM L - 7 3 5 , 8 2 1 were added to the tissue bath and 
measurements were repeated again. Subtracting current traces after application of the specific 
blockers for IRT or IRS in the presence of BaCh resulted in E - 4 0 3 1 or L - 7 3 5 , 8 2 1 sensitive 
currents, which can be considered as IR, or IRS, respectively. These E - 4 0 3 1 and L - 7 3 5 , 8 2 1 
sensitive currents, in the presence of BaCh, were compared to control IR, and IRS 
measurement to determine the possible effect of 10 pM BaCh on IRT and IRS. AS Figure 9 
shows, 10 pM BaCh did not significantly affect It0, IR, and IRS. Figure 9 indicate, however, 
that 1 0 pMBaCU inhibited I R I very effectively ( > 7 0 % ) suggesting that at this concentration 
BaCh can be used as a rather selective tool to inhibit IRI. 
Figure 10 shows that 10 pM BaCh alone lengthened APD in a reverse rate dependent 
manner inducing APD prolongation of 9.4+2.1% at cycle length of 300 ms (n=ll, P<0.05) 
and 33.0+3.3% at cycle length of 5000 ms (n=l 1, P<0.05). 
When the same concentration of BaCh was applied to preparations in which IR, was 
previously blocked by 1 pM dofetilide, BaCh induced a more excessive reverse-rate 
dependent further prolongation of APD (Figure 11). This excessive APD lengthening at long 
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cycle lengths frequently (in three out of seven experiments) resulted in early 
afterdepolarizations (EADs) as shown in Figure 12). 
Figure 6: Effect of chromanol 293B on the inward rectifier (Iki), transient outward (It0), 
rapid delayed rectifier (Ikt) and slow delayed rectifier (1^) potassium currents in dog 
ventricular myocytes. When measuring Ikt, L-735,821 (0.1 pM) was used to completely block 
IKS, and E-4031 (2 pM) was applied to block IKT when measuring The applied voltage 
protocols are shown in the insets and explained in the text in more detail. In all experiments 
lea was fully blocked by addition of 1 pM nisoldipine. The dotted lines represent the zero 
current levels. 
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Figure 7: Frequency dependent effect of IKS block (chromanol 293B) on the action 
potential duration in dog right ventricular papillary muscle. Note that the error bars are often 
smaller than the corresponding symbols. 
Figure 8: Frequency dependent effect of (dofetilide) and combined IKJ- (dofetilide) and 
IKS (chromanol 293B) block on the action potential duration in dog right ventricular papillary 
muscle. Note that the error bars are often smaller than the corresponding symbols, and the 
drug combination augmented the reverse rate dependent APD prolongation. 
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Figure 9: Effect of BaCl2 on the inward rectifier (Iki), transient outward (It0), rapid delayed 
rectifier (lie) and slow delayed rectifier (lie) potassium currents in dog ventricular myocytes. 
For measuring the effect of BaCl2 on lie the following protocol was used: (1) current 
recording under control conditions; (2) current recording in the presence of 10 pM BaCl2; (3) 
current recording after application of 2 pM E-4031 (in the presence of 10 pM BaCl2). 
Subtracting (3) from (2) gave the E-4031 sensitive current (i.e. lie) in the presence of 10 pM 
BaCl2. For measuring the effect of BaCl2 on lie a similar protocol was used but 0.1 pM L-
731,821 was applied for determining lie- The applied voltage protocols are shown in the 
insets, and explained in the text in more detail. In all experiments Ica was fully blocked by 
addition of 1 uM nisoldipine. The dotted lines represent the zero current levels. 
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Figure 10: Frequency dependent effect of IKi block (BaCl2) on the action potential duration 
in dog right ventricular papillary muscle. Note that the error bars are often smaller than the 
corresponding symbols. 
Figure 11: Frequency dependent effect of (dofetilide) and combined (dofetilide) and 
IKI (BaCF) block on the action potential duration in dog right ventricular papillary muscle. 
Note that the error bars are often smaller than the corresponding symbols, and the drug 
combination augmented the reverse rate dependent APD prolongation. 
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Figure 12: Early afterdepolarization (EAD) evoked by the combined IKT (dofetilide) and IKI 
(BaCli) block in dog right ventricular papillary muscle. 
5.3 Goal III: To elucidate the role oflfc and I & in normal human ventricular muscle. 
Effects of Iks and he- blockade on human ventricular muscle action potential duration 
Chromanol 293B (10 pM), L-735,821 (100 nM) and HMR-1556 (100 nM and 1 pM) 
reported to selectively block IKS in cardiac ventricular muscle preparations 
[18,29,30,31,48,43] in other species produced less than a 9 ms (2.8 %) change in human 
ventricular papillary muscle action potential duration after 40 min exposure, during 
continuous pacing at a cycle length of 1000 ms (Figure 13, upper and middle panels). In 
contrast, d-sotalol (30 pM) and E-4031 (1 pM) expected to selectively block IRT [18] 
markedly and significantly increased human ventricular muscle APD under identical 
conditions (Figure 13, bottom panels). This difference in the effects of chromanol 293 B (10 
pM), L-735,821 (100 nM) and HMR 1556 (100 nM and 1 pM) compared to d-sotalol (30 
pM) and E-4031 (1 pM) on APD was observed in human ventricular muscle over a wide 
range of pacing cycle lengths (300 to 5000 ms) (Figure 14). Over this range of pacing cycle 
lengths, either chromanol 293 B (Figure 14, open triangles), L-735,821 (open diamonds) or 
HMR (100 nM open circles and 1 pM open rectangles) produced no greater than a 12 ms (3.2 
30 
%) change in APD, while d-sotalol (closed circles) and E-4031 (closed rectangles) each 
markedly lengthened human ventricular APD in a reverse frequency-dependent manner. 
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Figure 13: Effects of chromanol 293B, HMR 1556, L-735, 821, E-4031 and d-sotalol on 
human ventricular muscle action potential duration. 
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Figure 14: Frequency dependent effects of chromanol 293B, HMR 1556, L-735, 821, E-
4031 and d-sotalol on human ventricular muscle action potential duration. 
Goal IV. To study the effect of ORM-10103, a newly developed NCX inhibitor devoid of Ica 
blocking property on the formation of EAD and DAD in the dog ventricular muscle and 
Purkinje fibers 
5.4 Effect of ORM-10103 on the formation of early and delayed afterdepolarisation 
Utilizing the conventional microelectrode technique, the effect of ORM-10103 on early 
(EAD) and delayed (DAD) afterdepolarizations was studied in dog right ventricular papillary 
muscles and in dog cardiac Purkinje fibers, respectively. 
EAD was evoked in the papillary muscle preparation, stimulated at slow cycle lengths 
(1500-3000 ms), by combination of 1 pM dofetilide and 10 pM BaCl?. As Figure 15 shows 1 
and 10 uM ORM-10103 decreased the amplitude of EAD. This effect was reversible upon 
washout of the compound from the tissue bath containing dofetilide and BaCU Similar effect 
was seen in 5 additional experiments. 3 pM ORM-10103 decreased the amplitude of EADs 
from 19.3±2.2 to 11.7±2.4 mV (n=6, p<0.05). At 10 pM the compound had a more 
pronounced effect decreasing EADs from 19.4±3.3 to 9.5±4.0 mV (n=4, p<0.05). 
A 10 pM Chromanol 293B (n=9) 
O 100 nM L-735,821 (n=7) 
O 100 nM HMR-1556 (n=7) 
• 1 pM HMR-1556 (n=7) 
+ 1 pM E-4031 (n=8) 
• 30 pM d-Sotalol (n=6) 
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DAD was evoked in Purkinje fiber preparations superfused with 0.2 pM Strophantin for 40 
min. In these experiments a train of 40 stimuli was applied with a cycle length of 400 ms in 
the train. The train was then followed with a stimulation free period of 20 s to observe DAD 
formation. Following addition of ORM-10103 the amplitude of DADs was decreased (Figure 
16). This effect was concentration-dependent; ORM-10103 decreased DAD amplitude at 3 
pM concentration from 5.5±0.6 to 2.4±0.8 mV (n=6, p<0.05) and at 10 uM from 8.1±2.3 to 
2.5±0.3 mV (n=5, p<0.05). In two experiments Strophantin evoked a run of extra beats 
appearing after the termination of the stimulus train which was abolished by application of 10 
pM ORM-10103. 
A B C D E 
CONTROL 1 uM DOFETILIDE 
+ 100 uM BaC} 
WASHOUT 
10 uM ORM-10103 (ORM-10103) 3 uM ORM-10103 
n 
0.2 s 1 s 
Figure 15: Effect of ORM-10103 on formation of early afterdepolarizations evoked by a 
combination of 1 pM dofetilide and 100 pM BaCl2 
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I I 
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CONTROL 0.2 pM STROPHANTIN STROPHANTIN + 3 pM ORM-10103 
I 
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Figure 16: Effect of ORM-10103 on formation of delayed afterdepolarizations evoked by 
0.2 pM Strophantin. 
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6. Discussion 
Multicellular electrophysiological recording techniques have turned out to be the cutting 
edge of scientific research methods again, since single cell systems have several shortcomings 
(deleterious effects of cell isolation on the transmembrane ion channels are poorly 
understood), and, consequently, physiological conditions are not adequate enough for 
measuring transmembrane action potentials, which are always a result of a fine balance of 
these transmembrane ion currents. Thus, methods using intracellular microelectrodes to 
measure action potentials are having their renaissance recently. Using this technique the sum 
of the inward and outward ion currents (action potential) can be measured in a contracting 
heart muscle preparation without the interference of their intracellular environment. Changes 
in parameters of the action potential while studying the effects of different drugs affect 
changes occuring in different ion currents. This method is stable and reliable, which appears 
to be its main advantage. 
The specific changes in the individual ion currents can be measured best using the patch 
clamp technique. However, when measuring the sum of these currents, i.e. the action 
potential, this method has the above mentioned shortcommings. Therefore, in my research 
project action potentials were always measured by the conventional intracellular 
microelectrode and transmembrane ion currents by the whole cell configuration of the patch-
clamp technique. 
6.1 Electrophysiological effects of terikalant 
Considering the advantages and disadvantages of the different electrophysiological 
techniques, we have chosen the measurements with intracellular microelectrodes to 
investigate the cellular electrophysiological action of terikalant in canine ventricular papillary 
muscle and Purkinje fiber preparations. Although the therapeutic free plasma level of 
terikalant is not fully established yet, it lies in the micromolar range [44]. Therefore, the 
concentrations applied in our experiments reflect therapeutically meaningful concentrations. 
Our findings showed that the main effect of terikalant is to lengthen APD90 (a Class III 
antiarrhythmic action) in low concentrations which is combined with Vmax block (Class I + 
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Class HI action) in higher concentrations. RP 58866 and its active enantiomer, terikalant were 
first considered as selective blockers of the inward rectifier potassium current (IRI) [13]. 
However, the selectivity of terikalant on IRI was later questioned [45], especially at high 
concentration. Accordingly, it was found that terikalant also inhibited the rapidly activating 
delayed-rectifier potassium current (IRJ). Later Williams et al. [46], consistent with the earlier 
results of Escande et al. [13], but in contrast to the results of Jurkiewicz et al. [44], found that 
only IRI was significantly affected by 10 pM terikalant, further increasing the uncertainity of 
the cellular mechanism of terikalant. 
Terikalant, like other Class IE antiarrhythmic drugs elicits reverse rate-dependent effect on 
the repolarization both in papillary muscle and Purkinje fibers. Also, as a new finding in our 
experiments, terikalant in addition to prolonging APD, depressed the maximal upstroke 
velocity of the action potential (Vmax) in a frequency-dependent manner. The offset kinetic 
time constant of Vmax block produced by the drug was calculated about 3 s, which value 
appears to be typical for Class I/A antiarrhythmic drugs. The onset kinetics of Vmax block 
induced by terikalant in this study was found to be rapid, resembling that of Class I/B 
antiarrhythmic drugs. Since the present study is the first to demonstrate the effect of terikalant 
on Vmax and on its offset and onset kinetics, our results may serve as a basis for its 
classification. It can thus be concluded that terikalant is a drug with combined Class ffl and 
IA antiarrhythmic actions with fairly rapid onset kinetics. The action potential lengthening 
effect of terikalant can be best explained by its well documented depressing effect on the 
cardiac transmembrane potassium currents [44]. The use-dependent block of Vmax is a new 
finding and reflects a diminution of the inward sodium current in accordance with the 
modulated receptor hypothesis [47]. 
In addition to the depression of the maximal upstroke velocity of the action potential 
(Vmax) which is due to the sodium channel inhibition, a possible proarrhvthmic effect could 
also appear via increasing the dispersion of repolarization. In fact, since the Cardiac 
Arrhythmia Supression Trial (CAST) [1], the development of potential antiarrhythmic drugs 
has been cancelled in cases of those novel compounds that turned out to have sodium channel 
blocking properties, especially the I/C subgroup. According to our results, besides its well 
established antiarrhythmic effects, terikalant may increase the proarrhythmic risk as well. 
As a conclusion, our study reveals that the investigational drug terikalant, in addition to its 
potassium channel inhibiting effect, also blocks the fast sodium channels in a rate-dependent 
manner and it possesses combined electrophysiological mode of action which most likely 
contributes to its established antiarrhythmic efficacy. 
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6.2 The role and interaction of the different potassium currents in the repolarization in dog 
ventricular muscle 
The most important finding of this study is that IRS or IRI inhibition resulted in an 
augmented reverse rate dependent repolarization lengthening in the presence of Irt block. 
In our experiments 10 pM chromanol 293B and 10 pM BaCl2 were applied in order to 
partially but selectively inhibit IRS and IRI, respectively. To apply these two agents at higher 
concentrations in which they would cause complete block of IRS and IRI was hampered by 
their known capability to inhibit various other potassium channels [48,49,50]. However, at the 
concentration of 10 pM, as our experiments demonstrate, they can be regarded as fairly 
selective blockers of IRS or IRI, respectively. In spite of this, it can not be entirely ruled out 
that chromanol 293B and BaCl2 at the applied concentration, can affect other, so far 
uninvestigated, transmembrane cardiac ion channels or electrogenic transport mechanisms. 
Further studies would be worthwhile to rule out or establish such possibilities. 
These results are in good agreement with the results of previous studies. The recent 
findings indicate that chromanol 293B alone only slightly lengthens APD in dog papillary 
muscle, but when APD is lengthened by previous superfusion of E-4031 and veratrine 
chromanol 293B resulted in a marked prolongation of APD [18], which can be explained by 
the kinetic properties of IRS. Accordingly, at longer APD IRS has more time to be activated and 
thereby it can more importantly contribute to repolarization. This led us to the conclusion that 
Irs could provide an important means of limiting excessive APD lengthening when action 
potentials are prolonged beyond normal by other mechanisms. In the present work we 
extended this previous observation, suggesting now that any kind of additive potassium 
channel block would greatly limit the capability of the ventricular muscle to repolarize. 
Vos et al. [51] developed an experimental torsade de pointes arrhythmia model in dogs, in 
which they found that after complete chronic atrioventricular block downregulation of Irs and 
IRT can be observed [35]. These animals showed longer QTc interval and monophasic APD, 
and had augmented susceptibility to develop torsade de pointes ventricular tachycardia after 
administration of certain Class III antiarrhythmic drugs [52]. It is also known that various 
potassium channels are down-regulated during heart failure [53], resulting in longer APD 
[54] and in increased risk of proarrhythmia. 
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In some forms of inherited long QT syndrome, like LQT1 and LQT2 [16,55], loss of 
functional potassium channel proteins or possible decrease of their density does not always 
result in marked or manifest QTc lengthening [56,57]. These patients, however, are 
susceptible to drugs, which can further depress the function of different types of potassium 
channels, and in such patients this can cause excessive and unexpected APD lengthening, 
often inducing torsade de pointes tachycardia. These observations strongly argue for the role 
of the so-called 'repolarization reserve' i.e. that different potassium channels may compensate 
each other to secure the repolarization process [58]. 
Similar to our results, very recently, Burashnikov & Antzelevitch [59] reported that 
attenuation of the repolarization reserve by combining IRT and IRS block can result in excessive 
APD lengthening and development of EADs. 
The present experiments may have some important therapeutical and practical 
implications. Based on these results it seems obvious that in situations where the 
'repolarization reserve' is decreased, minor loss of the function of the potassium channels 
may lead to excessive repolarization lengthening and under certain conditions to development 
of torsade de pointes arrhythmia. Therefore, patients admitted to hospital should be carefully 
tested how they respond to Class m antiarrhythmic drugs, and only those patients should 
receive long-term out of hospital treatment who respond to these drugs with QTc lengthening 
within the expected range. Similar conclusion can be drawn also from DIAMOND trial [60] 
as well, since dofetilide treatment proved to be neutral concerning overall mortality, but in a 
subgroup when mortality was related to QTc lengthening it was found that in patients in 
whom QTc lengthening was less, the dofetilide induced mortality figures tended to be 
favourable, but in patients where the QTc lengthening was above average, after dofetilide 
treatment, the mortality ratio was somewhat increased. 
Another possible implication of these results is that we should re-evaluate our safety 
pharmacology concepts related to drug induced QTc lengthening. Most of the routine safety 
pharmacology investigations are carried out in channel expression systems or in in vitro and 
in vivo tests performed in normal preparations where the 'repolarization reserve' is intact, 
frequently even at fast heart rates. In these situations the possible proarrhythmic danger of 
both cardiac and noncardiac investigational compounds is often underestimated, since the 
drugs may not cause significant APD lengthening under normal conditions, but in patients 
where the 'repolarization reserve' is impaired, the risk for excessive APD prolongation and 
consequently for torsade de pointes arrhythmia is greatly enhanced. Therefore, the preclinical 
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safety pharmacology screenings should be extended to preparations in which 'repolarization 
reserve' is attenuated. 
Goal III. To elucidate the role of I/cr and Iks in normal human ventricular muscle 
Our results indicate that in isolated, multicellular ventricular muscle obtained from normal, 
undiseased human hearts neither chromanol 293B nor L-735,821 and HMR-1556 markedly 
increased action potential over a range of pacing cycle lengths corresponding to heart rates of 
12 to 200 BPM. 
Contrasted to these findings, we demonstrated that E-4031 (1 pM), which blocks IK 
specifically, dramatically increased normal human ventricular muscle APD, as did sotalol (30 
pM), another recognized IK blocker that also dramatically increased human ventricular 
muscle APD under the same conditions that chromanol 293B and L-735,821 failed to. 
Stengl et al. [61] recently obtained results similar to our finding that I k block does not 
affect normal ventricular muscle action potential duration in species other than guinea pig. 
They reported that both in dog ventricular myocytes and papillary muscle preparations HMR-
1556 (an highly selective IK blocker) failed to lengthen APD without prior sympathetic 
simulation even at high concentrations. These authors concluded that IK block induced 
repolarization lengthening requires an elevated degree of sympathetic tone as may occur in 
heart failure. Others [62] have suggested that the sensitivity of action potential shortening by 
IK block is enhanced when phosphorylation is increased as expected during elevated 
sympathetic nervous activity. Clearly, cAMP increases IK and may alter its activation and 
deactivation kinetics so that IK may have different effects on APD when sympathetic tone is 
increased. This relation between phosphorylation and the effects of IK block on ventricular 
muscle APD needs further investigation to better elucidate its importance in normal and 
diseased human myocardium. 
Nonetheless, our present findings clearly indicate that neither chromanol 293B nor L-
735,821 and HMR-1556 markedly affect normal human ventricular muscle APD over a 
normal range of heart rates. Thus, IK normally plays little role in the repolarization of normal 
ventricular muscle action potentials. Rather, in normal human ventricular myocardium, IK is 
the outward current most responsible for termination of the action potential plateau and 
initiation of final action potential repolarization. However, as we have previously speculated, 
IK may play a vital role in normal myocardium when APD is prolonged as following a pause 
in rhythm, decreased levels of thyroid hormone, or hypothermia. Some investigators suggest 
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that as such IRs provides a "repolarization reserve" when other outward repolarizing currents 
are reduced; e.g., due to remodelling of ion currents during heart failure progression [63,64]. 
This role for Irs is supported by the finding that specific Irs block markedly lengthens dog 
papillary muscle APD after "repolarization reserve" is attenuated by complete IR, block with 1 
pM E-4031 (11,28). Clinical trials would be required to address such speculation. 
As an alternative explanation based on a recent study suggests that mutation of KvLQTl 
gene may decrease the trafficking of the HERG channel [65]. In this study it was found that 
coexpression of KvLQTl gene with the HERG gene increased the membrane 
immunolocalization of HERG channels by approximately 2-fold emphasizing the complexity 
of the possible phenotypic consequence of LQT syndroms. 
The findings report in this study suggest that development of ventricular antiarrhythmic 
strategies targeting selective Irs block are probably not warranted as they would not be 
expected to effect APD and refractoriness at normal heart rates while reducing "repolarization 
reserve." If, on the other hand, Irs could be therapeutically increased (either 
pharmacologically or genetically), arrhythmia risk might be reduced; certainly, such an 
antiarrhythmic intervention would benefit patients with inherited or acquired LQT. 
Therapeutic increases in Irs would increase "repolarization reserve" and possibly reduce the 
risk of sudden cardiac death during progression of heart failure where IR, and It0 expression 
are downregulated [63,64]. 
6.3 The electrophysiological effect of the NCX current inhibition 
The main finding of this study was that ORM-10103 effectively inhibited the NCX current 
without affecting Ica, and this effect was associated with a decrease of the amplitude of EAD 
and DAD evoked in dog ventricular papillary muscle and cardiac Purkinje fibers, 
respectively. In our experiments ORM-10103 inhibited the NCX current in dog ventricular 
myocytes at relatively low concentrations with an estimated IC50 of 0.8-0.9 pM. In the same 
cells ORM-10103, even at high concentration (10 pM), did not influence Ica measured by the 
patch clamp and IN3 determined as Vmax by the conventional microelectrode techniques. 
Consequently, decrease of inward currents and thereby diminution of Ca2+ load via the Ica and 
IN. can not explain the effect of ORM-10103 on EAD and DAD amplitude. Our unpublished 
data (not shown) indicate that ORM-10103 does not change the inward rectifier potassium 
current (IRI) and either does not change or slightly decreases the rapid delayed rectifier (IRT) 
and transient outward (It0) potassium currents. Therefore, participation of the major potassium 
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currents is also unlikely in the mechanism whereby ORM-10103 decreases EAD and DAD, 
although possible involvement of other transmembrane ionic currents, such as Ici and Na/K 
pump current, can not be completely ruled out. 
The only study which has recently described specific inhibition of the NCX current by a 
new compound, SEA 0400 [40], does not include the examination of the effect of this 
compound on arrhythmogenesis, EAD and DAD formation or on action potentials and 
contractility. KB-R7943 was reported to decrease NCX [66] and abolished experimental 
arrhythmias [37,38] but this compound can not be considered as specific inhibitor of NCX 
since it depresses the L-type calcium current, and it has other effects [40]. Therefore, our 
present investigation is the first which directly addresses the question whether specific NCX 
inhibition results in suppression of triggered arrhythmias in in vitro cardiac preparations. 
The possible therapeutic implication of our study appears to be rather complex. It is 
tempting to speculate that suppression of EAD and DAD may be antiarrhythmic both in the 
ventricles and the atria [67] during Ca2+ overload such as in heart failure and at the beginning 
of atrial flutter and fibrillation, especially when potassium currents may have been 
downregulated [68,69] and the NCX current upregulated [70], Also, it was considered that on 
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reperfusion after myocardial ischaemia, Ca influx occurs via the NCX in the reverse mode 
contributing to Ca2+ overload and triggering the release of Ca2+ from the sarcoplasmic 
reticulum and thereby causing cardiac arrhythmias [71]. Thus, blocking the reverse portion of 
the NCX current can also be beneficial. In addition, the positive inotropic effect of the 
inhibition of the forward mode of the NCX current can improve myocardial perfusion and, as 
such, it can be also beneficial. By specific NCX inhibition, unlike PDE inhibition, 
catecholamines and various calcium current activations, positive inotropic effect can be 
achieved without harmful electrophysiological consequences i.e. causing depolarization 
leading to EAD or DAD. 
On the other hand elevated intracellular Ca2+ concentration and enhanced cardiac force 
development may increase myocardial oxygen consumption, and if the Ca2+ extrusion systems 
other than NCX [72,73] can not properly compensate, the resulting excessive Ca2+ overload 
may affect the mitochondria and eventually may cause irreversible myocardial damage. 
7. Summary 
The most important findings in this PhD thesis are the following: 
41 
1. The in vitro electrophysiological effects of terikalant, this new investigational 
antiarrhythmic drug with largely unknown cellular mode of action, were studied which 
revealed that the investigational drug terikalant, in addition to its Class III potassium 
channel inhibiting effect, also blocked the fast sodium channels in a rate-dependent 
manner. In addition, like amiodarone, it possessed combined electrophysiological mode of 
action which most likely contributes to its established antiarrhythmic efficacy. 
2. The possible role and the interaction of different potassium channels in cardiac 
repolarization in dog ventricular muscle were also investigated. In the dog ventricular 
muscle when only one type of potassium channel is inhibited, excessive APD lengthening 
is not likely to occur. This is probably due to the capability of the various potassium 
channels to substitute each other. Dog ventricular myocytes seem to repolarize with a 
strong safety margin ('repolarization reserve'). When the normal 'repolarization reserve' is 
attenuated (due to drugs, remodelling or genetic disorders), the otherwise minimal or 
moderate potassium current inhibition can result in excessive and potentially 
proarrhythmic prolongation of the ventricular action potential duration. Also, application 
of drugs which are able to block more than one type of potassium channel is probably more 
hazardous than the use of specific inhibitors of a given potassium channel. We should 
reevaluate our safety pharmacology concept related to possible QT lengthening effect of 
drugs and apply tests in preparations where the 'repolarization reserve' is impaired instead 
of using preparations where this reserve is normal. 
3. The role of fa amd Irs were examined in human ventricular muscle. As we found 
earlier, Irs plays no obvious role in altering action potential repolarization and QT duration 
at normal heart rates in dog ventricular myocytes. In the present study, this finding is 
confirmed in isolated human ventricular preparations obtained from the hearts of 
individuals without heart disease. These findings should not be misconstrued as if Irs 
would not play an important role in the normal heart. In the healthy heart it prevents 
excessive action potential prolongation either following a single long diastolic interval 
occuring after the compensatory pause that follows a premature ventricular depolarization 
or during bradycardia. 
4. The effect of ORM-10103, a newly developed NCX inhibitor devoid of fa blocking 
property, on the formation of EAD and DAD in the dog ventricular muscle and Purkinje 
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fibers was investigated. -Evidence has been obtained for the NCX inhibitory activity of 
ORM-10103 and its potency to suppress elementary arrhythmogenic phenomena, such as 
EAD and DAD. Considering the pros and contras, further research is needed with both in 
vitro and in vivo methods to elucidate the potential therapeutic targets and, in a wider 
sense, the possible beneficial effect of specific NCX inhibition. 
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